|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.099 AUD | +2.06% |
|
-1.00% | -10.00% |
| May. 16 | PYC Therapeutics Completes Dosing for Eye Disease Trial; Shares Fall 5% | MT |
| May. 09 | Transcript : PYC Therapeutics Limited - Special Call |
PYC Therapeutics Limited reported earnings results for the full year ended June 30, 2022. For the full year, the company reported revenue was AUD 16.07 million compared to AUD 3.24 million a year ago. Net loss was AUD 13.86 million compared to AUD 17.77 million a year ago.
Basic loss per share from continuing operations was AUD 0.0044 compared to AUD 0.0057 a year ago. Diluted loss per share from continuing operations was AUD 0.0044 compared to AUD 0.0057 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.00% | 327M | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
PYC THERAPEUTICS LIMITED 